|Summary sheet: EPT|
|Routes of Administration|
N-Ethyl-N-propyltryptamine (also known as Ethylpropyltryptamine and EPT) is an obscure novel psychedelic substance of the tryptamine class. EPT is chemically related to DMT and belongs to a series of psychedelic compounds known as unsubstituted tryptamines.
The original synthesis date of EPT is unknown. It first appeared for sale on the online research chemical market in 2016. Unlike most research chemicals, EPT has no documentation in the scientific literature. It appears to be an entirely novel product of clandestine drug design.
Initial reports describe the effects of EPT as mild and indistinct compared to structurally similar base tryptamines such as DMT, DET and DPT, all of which are highly powerful psychedelics. Of these, it is reported to be most similar to DPT, albeit less potent and with a less immersive headspace.
EPT, or N-ethyl-N-propyltryptamine, is a synthetic indole molecule of the tryptamine chemical class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. EPT features one propyl and one ethyl groups bound to the terminal amine RN of its tryptamine backbone. EPT is the N-ethyl analog of DPT and the N-propyl analog of DET. It is also an analog of 4-HO-EPT and 4-AcO-EPT.
EPT is a unsubstituted tryptamine that is chemically related to DMT. The original synthesis date of EPT is unknown. It first appeared for sale on the online research chemical market in 2016. Unlike most research chemicals, EPT has no documentation in the scientific literature. It appears to be an entirely novel product of clandestine drug design. Ept is usually sold in its ethylpropyltryptamine fumarate form rather than the traditional HCl form that other tryptamines might be sold as.
Unfortunately, virtually no data exists about the metabolism and potential toxicity of EPT.
Like with most psychedelic tryptamines, EPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from EPT's binding efficacy at the 5-HT2A receptors. Most serotonergic psychedelic tryptamines have a very strong structural similarities to serotonin itself, which partially explains the affinity for certain 5-HT sites. It is almost unanimously agreed that most serotonergic psychedelics - such as EPT - produce their effect by acting as strong partial agonists at the 5-HT2A receptors.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a research literature based on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be regarded with a healthy degree of skepticism. It is worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce a full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include addiction, serious injury, or death ☠. The effects of EPT have not been researched as well as many other tryptamines. The following effects are drawn from a relatively limited sample size.
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational EPT use have not been studied in any scientific context and the exact toxic dose is unknown. This is because EPT is a research chemical with a very limited history of human usage.
Anecdotal evidence suggests that there are no negative health effects attributed to simply trying EPT by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Dependence and abuse potential
Unlike DMT, tolerance to the effects of EPT appears to form almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). EPT produces cross-tolerance with all psychedelics, meaning that after the consumption of EPT all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Due to its relative obscurity, the possession and sale of EPT is unscheduled in most countries.
- Germany: EPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Switzerland: EPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- United Kingdom: EPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: EPT is unscheduled in the United States. It may be considered an analogue of DMT, which is a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Italy: EPT is a Schedule 1 controlled substance.
This article does not cite enough references.
You can help by adding some.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- Tabella 1 (PDF), (in Italian), Ministero della Salute [Ministry of Health], p. 12. Retrieved 24 November, 2020.